lutetium Lu 177 vipivotide tetraxetan
View Patient InformationA radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.
Synonym: | 177Lu-labeled PSMA-617 177Lu-PSMA-617 Lu177-PSMA-617 lutetium Lu 177-PSMA-617 lutetium-177-PSMA-617 |
---|---|
US brand name: | Pluvicto |
Code name: | AAA 617 AAA-617 AAA617 |